MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
MacroGenics, Inc.NASDAQ: MGNX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables broadly unchanged from a year ago
Net receivables stood at $10.43M at the end of Q1 FY2026, down 1.1% from a year earlier and down 22.0% from the prior quarter. Over 3 fiscal years it compounded at -38.0% a year.
Context
- Net receivables amounted to 4.8% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -1.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 13.37M USD
- Year-over-year change
- +210.4%
- 4-year CAGR
- +6.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.37M | +210.4% |
| FY2024 | 2024-12-31 | 4.31M | -58.4% |
| FY2023 | 2023-12-31 | 10.37M | -81.6% |
| FY2022 | 2022-12-31 | 56.22M | +441.3% |
| FY2021 | 2021-12-31 | 10.39M | — |
Net Receivables vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.1% is the 2nd highest of 4, against a peer median of -2.4%.
- Net receivables amounts to 4.8% of total assets for MGNX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.43M USD | -1.1% | -38.0% | 4.8% | |
| Mar 2026 | $3.51M USD | +132.4% | -41.6% | 16.2% | |
| Mar 2026 | €1.65M EUR | -2.4% | -0.1% | 3.4% | |
| Dec 2025 | $161K USD | -84.7% | -11.5% | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MGNX) | — | -2.4% | -11.5% | 0.0% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 123.47M | 108.88M | 100.96M | 182.84M | 57.22M |
| Short-term Investments | 120.15M | 45.46M | 128.85M | 18.83M | 132.7M |
| Net Receivables | 10.39M | 56.22M | 10.37M | 4.31M | 13.37M |
| Inventory | 4.39M | 1.45M | 1.22M | 0 | 7.91M |
| Other Current Assets | 0 | 10.16M | 9.95M | 11.51M | 8.75M |
| Total Current Assets | 279.56M | 222.18M | 251.34M | 217.49M | 219.94M |
| Property, Plant & Equipment (Net) | 54.29M | 56.91M | 45.69M | 42.61M | 35.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 9.04M | 0 | 0 | 0 |
| Other Non-current Assets | 1.4M | 1.38M | 1.39M | 10.46M | 1.39M |
| Total Non-current Assets | 55.69M | 67.33M | 47.08M | 53.07M | 36.91M |
| Total Assets | 335.25M | 289.51M | 298.42M | 261.66M | 256.85M |
| Account Payables | 15.5M | 4.9M | 6.44M | 5.01M | 4.79M |
| Short-term Debt | 0 | 4.73M | 0 | 0 | 5.18M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 9.99M | 21.65M | 16.32M | 10.92M |
| Other Current Liabilities | 20.65M | 29M | 0 | 0 | 22.23M |
| Total Current Liabilities | 74.58M | 48.61M | 56.11M | 55.53M | 43.12M |
| Long-term Debt | 0 | 0 | 0 | 0 | 70M |
| Deferred Tax Liabilities | 0 | 9.04M | 0 | 8.9M | 0 |
| Deferred Revenue (Non-current) | 0 | 59.48M | 59.24M | 55.5M | 55.5M |
| Other Non-current Liabilities | 258K | 258K | 258K | 1.97M | 1.05M |
| Total Non-current Liabilities | 21.05M | 98.89M | 89.7M | 98.97M | 158.14M |
| Total Liabilities | 95.63M | 147.5M | 145.81M | 145.6M | 201.26M |
| Common Stock | 613K | 617K | 621K | 628K | 633K |
| Retained Earnings | (973.94M) | (1.09B) | (1.1B) | (1.17B) | (1.24B) |
| Accumulated OCI | (61K) | (5K) | (6K) | 4K | 32K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 239.62M | 142.01M | 152.61M | 116.06M | 55.59M |
| Total Debt | 25.47M | 34.83M | 33.97M | 37.46M | 106.76M |
| Net Debt | (98M) | (74.05M) | (66.99M) | (145.38M) | 49.55M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.